TLDR
- Ernexa Therapeutics posted a Q1 2026 net loss of $5.51M, down from $8.20M in Q1 2025.
- Diluted loss per share improved to $(6.95) from $(57.76) a year ago.
- The company ended Q1 with $9.2M cash, boosted by a $10.5M February public offering.
- Lead candidate ERNA-101 showed tumor clearance and 100% long-term survival in preclinical studies when combined with PD-1 therapy.
- Ernexa completed a 1-for-25 reverse stock split in May and filed a $50M shelf registration with an ATM program to address future cash needs.
Ernexa Therapeutics (ERNA) reported first-quarter 2026 results on May 11, with the stock surging over 78% on the day. The preclinical cell therapy company narrowed its net loss and gave investors an update on its pipeline.
Ernexa Therapeutics Inc., ERNA
The company posted a net loss of $5.51 million for Q1 2026, compared to a $8.20 million loss in the same period last year. That’s a $2.70 million improvement year-over-year.
Diluted loss per share came in at $(6.95), a sharp improvement from $(57.76) in Q1 2025. The year-ago figure reflects the pre-split share count, following Ernexa’s 1-for-25 reverse stock split which took effect May 4, 2026.
Operating expenses for the quarter totalled $5.6 million. That included $1.9 million in research and development costs, $1.6 million in general and administrative expenses, and a $2.0 million goodwill impairment charge.
Ernexa ended the quarter with $9.2 million in cash. That was helped by a February public offering that raised approximately $10.5 million in gross proceeds through common stock, pre-funded warrants, and milestone warrants.
Management flagged that April 30 cash of around $8.3 million falls below what the company expects to need over the next 12 months.
To bridge that gap, Ernexa filed a $50 million universal shelf registration and set up an at-the-market (ATM) program, through which it expects access to up to $9.2 million.
ERNA-101 Shows Early Promise
On the pipeline side, ERNA-101, the company’s lead oncology candidate, showed tumor growth reduction in preclinical models. When combined with PD-1 therapy, it produced tumor clearance and 100% long-term survival in the reported studies.
Those are preclinical results — the real test comes in humans. Ernexa says it completed a pre-IND meeting with the FDA and plans to submit an IND application later in 2026, with a Phase I investigator-sponsored trial targeted for H2 2026.
The company is also advancing ERNA-201, an IL-10-secreting iMSC therapy for autoimmune conditions, and is pursuing strategic partnerships and grants to support development.
Japan Expansion and Compliance Steps
Beyond the pipeline, Ernexa was accepted into a Japan trade acceleration program aimed at supporting market entry in that country.
The reverse stock split, which left 1,166,333 common shares outstanding as of May 8, 2026, was partly a compliance move. Ernexa expects it will help the company regain Nasdaq bid-price compliance.
As of March 31, 2026, the company had 1,166,333 common shares outstanding after the split was applied retroactively.
🚨 Our MAY Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for May, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
